EP3356390A4 - METHODS AND COMPOSITIONS FOR VIRAL VECTORS AVOIDING ANTIBODIES - Google Patents
METHODS AND COMPOSITIONS FOR VIRAL VECTORS AVOIDING ANTIBODIES Download PDFInfo
- Publication number
- EP3356390A4 EP3356390A4 EP16852471.8A EP16852471A EP3356390A4 EP 3356390 A4 EP3356390 A4 EP 3356390A4 EP 16852471 A EP16852471 A EP 16852471A EP 3356390 A4 EP3356390 A4 EP 3356390A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- avoiding
- compositions
- methods
- viral vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL16852471T PL3356390T3 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
| EP20212583.7A EP3831842A1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234016P | 2015-09-28 | 2015-09-28 | |
| PCT/US2016/054143 WO2017058892A2 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20212583.7A Division EP3831842A1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
| EP20212583.7A Division-Into EP3831842A1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3356390A2 EP3356390A2 (en) | 2018-08-08 |
| EP3356390A4 true EP3356390A4 (en) | 2019-08-28 |
| EP3356390B1 EP3356390B1 (en) | 2021-01-20 |
Family
ID=58424549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16852471.8A Active EP3356390B1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
| EP20212583.7A Withdrawn EP3831842A1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20212583.7A Withdrawn EP3831842A1 (en) | 2015-09-28 | 2016-09-28 | Methods and compositions for antibody-evading virus vectors |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10745447B2 (en) |
| EP (2) | EP3356390B1 (en) |
| JP (3) | JP7064214B2 (en) |
| CN (2) | CN114606267A (en) |
| AU (2) | AU2016332821B2 (en) |
| BR (1) | BR112018003665A2 (en) |
| CA (1) | CA2996420A1 (en) |
| DK (1) | DK3356390T3 (en) |
| ES (1) | ES2865487T3 (en) |
| IL (4) | IL292830B2 (en) |
| PL (1) | PL3356390T3 (en) |
| PT (1) | PT3356390T (en) |
| SG (1) | SG10202107733QA (en) |
| WO (1) | WO2017058892A2 (en) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6985795B2 (en) | 2013-09-26 | 2021-12-22 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | Synthetic combinatorial AAV capsid library for targeted gene therapy |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN114717264A (en) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | Compositions and methods for treating amyotrophic lateral sclerosis (ALS) |
| CN107207556B (en) | 2014-11-14 | 2020-12-08 | 沃雅戈治疗公司 | regulatory polynucleotide |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| US12188037B2 (en) | 2015-10-22 | 2025-01-07 | University Of Florida Research Foundation, Incorporated | Synthetic combinatorial AAV3 capsid library |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR DETECTION OF NEUTRALIZING ANTIBODIES OF VAA |
| US11124546B2 (en) * | 2015-12-14 | 2021-09-21 | The University Of North Carolina At Chapel Hill | Modified capsid proteins for enhanced delivery of parvovirus vectors |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR102652994B1 (en) | 2016-05-18 | 2024-04-01 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Preparations and methods for treating Huntington's disease |
| EP3500676A4 (en) * | 2016-08-16 | 2020-07-01 | The University of North Carolina at Chapel Hill | METHOD AND COMPOSITIONS FOR TARGETED GENE TRANSFER |
| EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| CA3114549A1 (en) | 2017-02-21 | 2018-08-30 | University Of Florida Research Foundation, Incorporated | Modified aav capsid proteins and uses thereof |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| CN111108198A (en) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | Compositions and methods for treating Huntington's disease |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| AU2018302016A1 (en) | 2017-07-17 | 2020-02-06 | The Regents Of The University Of California | Trajectory array guide system |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| WO2019067840A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| CA3077426A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| EP4509527A3 (en) * | 2017-10-18 | 2025-04-30 | REGENXBIO Inc. | FULLY HUMAN POSTSTRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTIC AGENTS |
| CN112041442A (en) * | 2018-02-28 | 2020-12-04 | 北卡罗来纳大学查佩尔希尔分校 | Methods and compositions for viral vectors to evade antibodies |
| BR112020018354A2 (en) * | 2018-03-16 | 2020-12-29 | Research Institute At Nationwide Children's Hospital | INCREASED SPECIFIC GENE SUPPLY TO TISSUE THROUGH CAPSIDE MODIFICATION |
| WO2019191716A1 (en) * | 2018-03-29 | 2019-10-03 | University Of Florida Research Foundation, Incorporated | Aav6 variants |
| CA3095127A1 (en) * | 2018-03-29 | 2019-10-03 | Asklepios Biopharmaceutical, Inc. | Liver tropic recombinant aav6 vectors that evade neutralization |
| KR20210006358A (en) | 2018-04-03 | 2021-01-18 | 스트라이드바이오 인코포레이티드 | Viral vectors for targeting the inner tissues |
| AU2019247746B2 (en) * | 2018-04-03 | 2024-08-15 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| AU2019247748A1 (en) * | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| JP2021523702A (en) * | 2018-05-04 | 2021-09-09 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Human anti-AAV2 capsid polyclonal antibody epitope |
| US20210230632A1 (en) | 2018-05-15 | 2021-07-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CA3099306A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| JP7142815B2 (en) * | 2018-06-21 | 2022-09-28 | 株式会社遺伝子治療研究所 | Adeno-associated virus virions for gene transfer into human liver |
| MX2021000810A (en) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Systems and methods for producing gene therapy formulations. |
| CA3114199A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113166208B (en) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | Redirecting the tropism of AAV capsids |
| TW202035689A (en) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | Methods for measuring the titer and potency of viral vector particles |
| EP3861107A1 (en) | 2018-10-05 | 2021-08-11 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| TW202039858A (en) | 2019-01-18 | 2020-11-01 | 美商航海家醫療公司 | Methods and systems for producing aav particles |
| JP2022520647A (en) | 2019-02-15 | 2022-03-31 | サンガモ セラピューティクス， インコーポレイテッド | Compositions and Methods for Recombinant AAV Production |
| MX2021011468A (en) | 2019-03-21 | 2021-12-15 | Recombinant adeno-associated virus vectors. | |
| WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP3999120A4 (en) * | 2019-07-04 | 2024-02-21 | Children's Medical Research Institute | METHOD AND AAV VECTORS FOR IN VIVO TRANSDUCTION |
| US20220265853A1 (en) * | 2019-07-12 | 2022-08-25 | Gene Therapy Research Institution Co., Ltd. | Adeno-associated virus virion for gene transfer to human liver |
| CN110295151A (en) * | 2019-07-17 | 2019-10-01 | 博鑫仪器(天津)有限公司 | A kind of gland dependovirus virus recombinant plasmid, recombinant virus and construction method |
| EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| RU2751592C2 (en) * | 2019-08-22 | 2021-07-15 | Общество С Ограниченной Ответственностью "Анабион" | Isolated modified vp1 capsid protein of adeno-associated virus of serotype 5 (aav5), capsid and vector based on it |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| WO2021076925A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| US20230340526A1 (en) * | 2019-11-25 | 2023-10-26 | University Of Florida Research Foundation, Incorporated | Novel aav3b variants that target hepatocytes and evade the humoral immune response |
| JP2021097617A (en) * | 2019-12-20 | 2021-07-01 | 学校法人自治医科大学 | Adeno-associated virus virion for treatment of ornithine transcarbamylase deficiency |
| IL297577A (en) | 2020-05-05 | 2022-12-01 | Univ Duke | Cross-species compatible adeno-associated virus compositions and methods of use thereof |
| CA3182970A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| US20230227802A1 (en) | 2020-07-27 | 2023-07-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| IL300717A (en) | 2020-08-19 | 2023-04-01 | Sarepta Therapeutics Inc | Adeno-associated virus vectors for treatment of rett syndrome |
| CN111925438B (en) * | 2020-08-28 | 2021-03-09 | 和元生物技术（上海）股份有限公司 | Antibodies capable of binding to AAV1-13 |
| US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022229703A2 (en) * | 2021-04-30 | 2022-11-03 | Takeda Pharmaceutical Company, Ltd. | New aav8 based immune escaping variants |
| AR126839A1 (en) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | MODIFIED VP1 CAPSID PROTEIN ISOLATED FROM ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED ON THIS |
| IL311871A (en) | 2021-10-08 | 2024-06-01 | Dyno Therapeutics Inc | Capsid variants and methods of using the same |
| JP2024540221A (en) | 2021-11-02 | 2024-10-31 | ボイジャー セラピューティクス インコーポレイテッド | AAV capsid variants and uses thereof |
| EP4442830A4 (en) | 2021-11-29 | 2025-04-30 | Shanghai Regenelead Therapies Co., Ltd. | AADC/GDNF POLYNUCLEOTIDE AND ITS USE IN THE TREATMENT OF PARKINSON'S DISEASE |
| WO2023150687A1 (en) | 2022-02-04 | 2023-08-10 | Ginkgo Bioworks, Inc. | Recombinant adeno-associated virus vectors, and methods of use thereof |
| TW202342526A (en) | 2022-02-21 | 2023-11-01 | 大陸商上海瑞宏迪醫藥有限公司 | Vegf-binding molecule and the pharmaceutical use thereof |
| CN119095866A (en) * | 2022-02-22 | 2024-12-06 | 北卡罗来纳大学查佩尔希尔分校 | Chimeric neurotropic AAV capsids |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN115850415B (en) * | 2022-09-14 | 2024-05-28 | 青岛农业大学 | A PbCaM7 gene, protein and application thereof |
| KR102855674B1 (en) * | 2022-10-06 | 2025-09-08 | 주식회사 글루진테라퓨틱스 | Adeno-associated virus vector capable of lung bronchial-specific gene delivery |
| TW202502803A (en) | 2023-03-10 | 2025-01-16 | 美商戴諾治療公司 | Capsid polypeptides and methods of use thereof |
| EP4680619A1 (en) * | 2023-03-13 | 2026-01-21 | Agency for Science, Technology and Research | Engineered adeno-associated viruses |
| WO2025008323A1 (en) | 2023-07-03 | 2025-01-09 | UCB Biopharma SRL | Engineered aav capsid proteins |
| WO2025049993A1 (en) | 2023-08-31 | 2025-03-06 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025121957A1 (en) * | 2023-12-06 | 2025-06-12 | 주식회사 글루진테라퓨틱스 | Adeno-associated virus variants capable of brain astrocyte-specific gene transfer and applications thereof |
| WO2025171227A1 (en) | 2024-02-08 | 2025-08-14 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| CN120842371B (en) * | 2025-09-25 | 2025-11-21 | 北京溯本源和生物科技有限公司 | A monoclonal antibody 5F11 capable of broadly recognizing multiple AAV antigens and its applications |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287122A1 (en) * | 2001-01-05 | 2005-12-29 | Children's Hospital Inc. | AAV vectors and methods |
| WO2015121501A1 (en) * | 2014-02-17 | 2015-08-20 | King's College London | Adeno-associated virus vector |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1453547A (en) | 1922-05-18 | 1923-05-01 | Doyle | Barrel-holding device |
| US1777296A (en) | 1928-08-22 | 1930-10-07 | Superior Locker Company | Indicating device for locker doors |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| WO1988002026A1 (en) | 1986-09-08 | 1988-03-24 | Applied Biotechnology, Inc. | Empty viral capsid vaccines |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| WO1990005142A1 (en) | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
| US5916563A (en) | 1988-11-14 | 1999-06-29 | United States Of America | Parvovirus protein presenting capsids |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| ES2026826A6 (en) | 1991-03-26 | 1992-05-01 | Ercros Sa | Method for producing a subunit vaccine against the canine parvovirus and other related viruses. |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| ATE452981T1 (en) | 1995-06-07 | 2010-01-15 | Univ North Carolina | TRANSDUCTION OF MYOBLASTS USING VECTORS FROM ADENO-ASSOCIATED VIRUSES |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| ES2279531T3 (en) | 1995-12-15 | 2007-08-16 | Intronn, Inc. | THERAPEUTIC MOLECULES GENERATED BY CUTTING AND EMPALME IN TRANS. |
| US20030215422A1 (en) | 1996-09-11 | 2003-11-20 | John A. Chiorini | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| CA2329060C (en) | 1998-05-28 | 2011-09-13 | John A. Chiorini | Aav5 vector and uses thereof |
| US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
| US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
| US8299321B2 (en) | 1998-06-16 | 2012-10-30 | Monsanto Technology Llc | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20100293663A2 (en) | 1998-06-16 | 2010-11-18 | Thomas La Rosa | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| DE19830522A1 (en) | 1998-07-08 | 2000-01-13 | Pritt Produktionsgesellschaft | Device for transferring a substance applied in the form of a film to a carrier tape |
| WO2000017377A2 (en) | 1998-09-22 | 2000-03-30 | University Of Florida | Methods for large-scale production of recombinant aav vectors |
| GB9822763D0 (en) | 1998-10-20 | 1998-12-16 | Univ Sheffield | Immunoglobin variant |
| PT1127150E (en) | 1998-11-05 | 2007-08-22 | Univ Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US6822071B1 (en) | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
| EP1033405A3 (en) | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| EP1887081A2 (en) | 1999-02-25 | 2008-02-13 | Ceres Incorporated | DNA Sequences |
| US20130326723A1 (en) | 1999-05-06 | 2013-12-05 | Thomas J. La Rosa | Soy nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20110214206A1 (en) | 1999-05-06 | 2011-09-01 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with plants |
| US20110093981A9 (en) | 1999-05-06 | 2011-04-21 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with transcription in plants and uses thereof for plant improvement |
| US20080229439A1 (en) | 1999-05-06 | 2008-09-18 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with transcription in plants and uses thereof for plant improvement |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US6498244B1 (en) * | 1999-05-28 | 2002-12-24 | Cell Genesys, Inc. | Adeno-associated virus capsid immunologic determinants |
| US7314912B1 (en) | 1999-06-21 | 2008-01-01 | Medigene Aktiengesellschaft | AAv scleroprotein, production and use thereof |
| DE19933288A1 (en) * | 1999-07-15 | 2001-01-18 | Medigene Ag | Structural protein of adeno-associated virus with altered antigenicity, its production and use |
| AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US20140130203A1 (en) | 2000-04-19 | 2014-05-08 | Thomas J. La Rosa | Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| JP2004520803A (en) | 2000-04-21 | 2004-07-15 | コリクサ コーポレイション | Compositions and methods for the treatment and diagnosis of acne vulgaris |
| ES2256265T3 (en) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | DUVICATED PARVOVIRUS VECTORS. |
| AU2001268149B2 (en) | 2000-06-01 | 2005-08-18 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| JP2002130156A (en) | 2000-10-20 | 2002-05-09 | Anest Iwata Corp | Scroll fluid machine having multistage type fluid compressing part |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| AU2002341541A1 (en) | 2001-06-22 | 2003-03-03 | Syngenta Participations Ag | Abiotic stress responsive polynucleotides and polypeptides |
| AU2002345250A1 (en) | 2001-06-22 | 2003-01-08 | Syngenta Participations Ag | Plant disease resistance genes |
| US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
| WO2002010210A2 (en) | 2001-08-28 | 2002-02-07 | Bayer Cropscience Ag | Polypeptides for identifying herbicidally active compounds |
| WO2003033515A1 (en) | 2001-10-15 | 2003-04-24 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
| CA2467959C (en) | 2001-11-09 | 2009-03-10 | Robert M. Kotin | Production of adeno-associated virus in insect cells |
| SG10201506627PA (en) * | 2001-11-13 | 2015-10-29 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2975413T3 (en) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors that contain them and their uses |
| ES2526341T3 (en) | 2001-12-17 | 2015-01-09 | The Trustees Of The University Of Pennsylvania | Sequences of serotype 9 of adeno-associated virus (AAV), vectors containing them, and uses thereof |
| US7071172B2 (en) | 2002-04-30 | 2006-07-04 | The University Of North Carolina At Chapel Hill | Secretion signal vectors |
| AU2003295312B2 (en) | 2002-05-01 | 2008-08-14 | University Of Florida Research Foundation, Inc. | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| ITRM20020253A1 (en) | 2002-05-08 | 2003-11-10 | Univ Roma | SNRNA CHEMICAL MOLECULES WITH ANTISENSE SEQUENCES FOR SPLICING JUNCTIONS OF THE DYSTROPHINE GENE AND THERAPEUTIC APPLICATIONS. |
| JP2005185101A (en) | 2002-05-30 | 2005-07-14 | National Institute Of Agrobiological Sciences | Plant full-length cDNA and use thereof |
| PT2263692T (en) | 2002-12-24 | 2018-11-28 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
| CA2528012C (en) | 2003-06-02 | 2015-11-24 | University Of Massachusetts | Methods and compositions for controlling efficacy of rna silencing |
| PT2657248T (en) | 2003-06-19 | 2017-06-26 | Genzyme Corp | Aav virions with decreased immunoreactivity and uses therefor |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US20060107345A1 (en) | 2003-09-30 | 2006-05-18 | Nickolai Alexandrov | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| CN102212558B (en) | 2003-09-30 | 2016-08-03 | 宾夕法尼亚大学托管会 | Adeno associated virus (AAV) is evolved, sequence, carrier containing these sequences and their application |
| KR101637908B1 (en) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| FR2874384B1 (en) | 2004-08-17 | 2010-07-30 | Genethon | ADENO-ASSOCIATED VIRAL VECTOR FOR PRODUCING EXON JUMP IN A GENE ENCODING A PROTEIN WITH DISPENSABLE DOMAINS |
| JP4346526B2 (en) | 2004-08-31 | 2009-10-21 | 株式会社東芝 | Semiconductor integrated circuit device |
| US7366250B2 (en) | 2004-09-09 | 2008-04-29 | Agere Systems Inc. | Method and apparatus for improved efficiency in an extended multiple antenna communication system |
| WO2006029319A2 (en) | 2004-09-09 | 2006-03-16 | The General Hospital Corporation | Modulating phosphatase activity in cardiac cells |
| NZ555830A (en) * | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
| CN101137390B (en) | 2005-01-05 | 2013-03-27 | 盐野义制药株式会社 | Novel angiogensis inhibitor |
| WO2006092449A2 (en) | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
| EP2573188A2 (en) | 2005-03-02 | 2013-03-27 | Metanomics GmbH | Process for the production of fine chemicals |
| WO2006119137A1 (en) | 2005-04-29 | 2006-11-09 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of nucleic acid at post-transcriptional level |
| EP1882392A4 (en) | 2005-05-10 | 2009-07-01 | Monsanto Technology Llc | Genes and uses for plant improvement |
| WO2007084773A2 (en) | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| WO2007089632A2 (en) | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| AU2007221470B2 (en) | 2006-02-10 | 2013-02-14 | The University Of Cincinnati | Phosphatase inhibitor Protein-1 as a regulator of cardiac function |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US20090317417A1 (en) * | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
| US9198984B2 (en) | 2006-04-28 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Scalable production method for AAV |
| CN103849629B (en) | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | Carrier with the modified AAV REP78 translation initiation codons for producing AAV in insect cell |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| PL2191001T4 (en) * | 2007-04-09 | 2017-01-31 | University Of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
| US9611302B2 (en) * | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
| CN103695459A (en) | 2007-09-18 | 2014-04-02 | 巴斯夫植物科学有限公司 | Plants with increased yield |
| BRPI0907786B1 (en) | 2008-02-20 | 2021-06-01 | Ceres, Inc. | METHOD OF PRODUCTION OF A PLANT AND METHOD OF INCREASING THE LEVEL OF TOLERANCE TO LOW NITROGEN IN A PLANT |
| US20090215879A1 (en) | 2008-02-26 | 2009-08-27 | University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| MX2010012592A (en) | 2008-05-20 | 2011-05-05 | Eos Neuroscience Inc | Vectors for delivery of light-sensitive proteins and methods of use. |
| JP2010002479A (en) | 2008-06-18 | 2010-01-07 | Crossfor:Kk | Jewelry article for lens of eyeglasses and jewelry-installation tool for eyeglasses |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| SG10202109219SA (en) | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2292781A1 (en) | 2009-08-17 | 2011-03-09 | Genethon | Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| ES2698203T3 (en) | 2010-04-23 | 2019-02-01 | Univ Massachusetts | AAV vectors that are directed to the SNC and methods of using them |
| US9839696B2 (en) | 2010-04-30 | 2017-12-12 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| DK2673289T3 (en) * | 2011-02-10 | 2023-07-24 | Univ North Carolina Chapel Hill | VIRUS VECTORS WITH MODIFIED TRANSDUCTION PROFILES AND METHODS FOR THEIR PRODUCTION AND USE |
| US10392632B2 (en) | 2011-02-14 | 2019-08-27 | The Children's Hospital Of Philadelphia | AAV8 vector with enhanced functional activity and methods of use thereof |
| CA3177736A1 (en) | 2011-08-23 | 2013-02-28 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
| FI124176B (en) | 2011-12-01 | 2014-04-15 | Helsingin Yliopisto | Polypeptide, polynucleotide, expression cassette, vector, host cell, plant and uses |
| PE20150163A1 (en) | 2012-04-18 | 2015-02-23 | Philadelphia Children Hospital | COMPOSITION AND METHODS FOR A HIGHLY EFFICIENT GENE TRANSFER USING CAPSID AAV VARIANTS |
| EP2660325A3 (en) | 2012-05-02 | 2014-02-12 | Christian Medical College | AAV vectors and corresponding nucleotide sequences and methods |
| US9677088B2 (en) | 2012-05-09 | 2017-06-13 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| US10294281B2 (en) * | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| EP2492347A1 (en) | 2012-05-22 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Methods for the production of vectors |
| EP2864488A1 (en) | 2012-06-21 | 2015-04-29 | Association Institut de Myologie | Widespread gene delivery of gene therapy vectors |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| US10266845B2 (en) | 2013-02-08 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| EP2968605B1 (en) * | 2013-03-15 | 2022-07-27 | The University of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav vectors |
| CN111763690A (en) | 2013-05-21 | 2020-10-13 | 佛罗里达大学研究基金会有限公司 | Capsid-modified RAAV3 vector composition and use in human liver cancer gene therapy |
| CN105247044B (en) | 2013-05-31 | 2021-05-07 | 加利福尼亚大学董事会 | Adeno-associated virus variants and methods of use |
| PH12016500162B1 (en) | 2013-07-22 | 2024-02-21 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene trnsfer to cells, organs, and tissues |
| ES2739288T3 (en) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Selective recovery |
| JP6985795B2 (en) | 2013-09-26 | 2021-12-22 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | Synthetic combinatorial AAV capsid library for targeted gene therapy |
| PT3459965T (en) | 2013-10-11 | 2021-02-25 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| CN104592364B (en) * | 2013-10-30 | 2018-05-01 | 北京大学 | The adeno-associated virus of rite-directed mutagenesis and pointed decoration, its preparation method and application |
| WO2015127128A2 (en) | 2014-02-19 | 2015-08-27 | University Of Massachusetts | Recombinant aavs having useful transcytosis properties |
| WO2015126972A1 (en) | 2014-02-21 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Methods and compositions for gene delivery to on bipolar cells |
| ES2768763T3 (en) | 2014-03-04 | 2020-06-23 | Univ Florida | Enhanced rAAV vectors and methods for transduction of photoreceptors and EPR cells |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| CA2946593A1 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
| MX384480B (en) | 2014-05-28 | 2025-03-14 | Evogene Ltd | ISOLATED POLYNUCLEOTIDES, POLYPEPTIDES AND METHODS OF USING THEM TO INCREASE ABIOTIC STRESS TOLERANCE, BIOMASS AND YIELD OF PLANTS. |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CA3179824A1 (en) | 2014-06-25 | 2015-12-30 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| PL3198018T3 (en) | 2014-09-24 | 2021-07-19 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
| AU2015335923B2 (en) | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| CN114480440A (en) | 2014-11-21 | 2022-05-13 | 北卡罗来纳-查佩尔山大学 | AAV vectors targeting the central nervous system |
| EP3245220B1 (en) | 2015-01-14 | 2023-09-20 | The University of North Carolina at Chapel Hill | Methods and compositions for targeted gene transfer |
| WO2016126857A1 (en) * | 2015-02-03 | 2016-08-11 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| US20180135074A1 (en) * | 2015-02-19 | 2018-05-17 | University Of Florida Research Foundation, Incorporated | Recombinant aav vectors for gene therapy of human hematopoietic disorders |
| MY187898A (en) | 2015-03-02 | 2021-10-27 | Adverum Biotechnologies Inc | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| CN107532177A (en) | 2015-03-24 | 2018-01-02 | 加利福尼亚大学董事会 | Adeno-associated virus variant and its application method |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| US20180104289A1 (en) | 2015-04-08 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Viral gene therapy as treatment for cholesterol storage disease or disorder |
| CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
| WO2016179644A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Research Institute | Promoters for expression of heterologous genes |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| EP3294894B8 (en) | 2015-05-12 | 2019-09-25 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone |
| WO2017015102A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for achieving high levels of transduction in human liver cells |
| CA2988471A1 (en) | 2015-07-28 | 2017-02-02 | University Of Massachusetts | Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector |
| HUE061388T2 (en) | 2015-07-30 | 2023-06-28 | Massachusetts Eye & Ear Infirmary | Ancestral aav sequences and uses thereof |
| WO2017066764A2 (en) | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses |
| CA3002980A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| CN108603174A (en) | 2015-12-01 | 2018-09-28 | 星火治疗有限公司 | A scalable method for the production of recombinant adeno-associated virus (AAV) vectors in a serum-free suspension cell culture system suitable for clinical applications |
| US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
| US10385320B2 (en) | 2015-12-02 | 2019-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| US11124546B2 (en) | 2015-12-14 | 2021-09-21 | The University Of North Carolina At Chapel Hill | Modified capsid proteins for enhanced delivery of parvovirus vectors |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| CN109415704B (en) | 2016-02-16 | 2022-02-25 | 利兰斯坦福初级大学董事会 | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
| CN108697774A (en) | 2016-02-22 | 2018-10-23 | 北卡罗来纳大学教堂山分校 | Treat the AAV-IDUA carriers of MPS I- correlations blindness |
| IL298604A (en) | 2016-04-15 | 2023-01-01 | Univ Pennsylvania | Novel aav8 mutant capsids and preparations containing them |
| WO2017192750A1 (en) | 2016-05-04 | 2017-11-09 | Oregon Health & Science University | Recombinant adeno-associated viral vectors |
| AU2017261812B2 (en) | 2016-05-13 | 2019-04-18 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| KR102652994B1 (en) | 2016-05-18 | 2024-04-01 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
| WO2018017956A2 (en) | 2016-07-21 | 2018-01-25 | Spark Therapeutics, Inc. | Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby |
| EP3491008A2 (en) | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| EP3500676A4 (en) | 2016-08-16 | 2020-07-01 | The University of North Carolina at Chapel Hill | METHOD AND COMPOSITIONS FOR TARGETED GENE TRANSFER |
| WO2018064624A1 (en) | 2016-09-29 | 2018-04-05 | University Of Florida Research Foundation, Incorporated | Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| US20230048025A1 (en) | 2016-12-22 | 2023-02-16 | Oregon Health & Science University | Adeno associated viral vectors |
| IL268534B2 (en) | 2017-02-15 | 2024-10-01 | Univ North Carolina Chapel Hill | Methods and compounds for gene delivery across the vasculature |
| SG10201912973XA (en) | 2017-02-28 | 2020-03-30 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
| CN110770346B (en) | 2017-03-15 | 2024-01-12 | 北卡罗来纳-查佩尔山大学 | Polyploid adeno-associated virus vectors and methods for their preparation and use |
| AU2018265414B2 (en) | 2017-05-10 | 2022-01-20 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses |
| WO2018237066A1 (en) | 2017-06-20 | 2018-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions |
| WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
| ES2957622T3 (en) | 2018-01-17 | 2024-01-23 | Meiragtx Uk Ii Ltd | Modified rAAV capsid protein for gene therapy |
| IL276859B2 (en) | 2018-02-27 | 2025-12-01 | Univ Pennsylvania | Novel adeno-associated virus (AAV) vectors, AAV vectors with reduced capsid deamidation and uses therefor |
| CN112236443B (en) | 2018-02-27 | 2025-02-07 | 宾夕法尼亚州大学信托人 | Novel adeno-associated virus (AAV) vectors, AAV vectors with reduced capsid deamidation and uses thereof |
| CN112041442A (en) | 2018-02-28 | 2020-12-04 | 北卡罗来纳大学查佩尔希尔分校 | Methods and compositions for viral vectors to evade antibodies |
| US20210010028A1 (en) | 2018-03-06 | 2021-01-14 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
| EP3762501A4 (en) | 2018-03-06 | 2022-03-09 | University of Florida Research Foundation, Incorporated | VAA CHIMERAS |
| BR112020018354A2 (en) | 2018-03-16 | 2020-12-29 | Research Institute At Nationwide Children's Hospital | INCREASED SPECIFIC GENE SUPPLY TO TISSUE THROUGH CAPSIDE MODIFICATION |
| KR20210006358A (en) | 2018-04-03 | 2021-01-18 | 스트라이드바이오 인코포레이티드 | Viral vectors for targeting the inner tissues |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| AU2019247746B2 (en) | 2018-04-03 | 2024-08-15 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
-
2016
- 2016-09-28 IL IL292830A patent/IL292830B2/en unknown
- 2016-09-28 ES ES16852471T patent/ES2865487T3/en active Active
- 2016-09-28 IL IL299901A patent/IL299901B2/en unknown
- 2016-09-28 BR BR112018003665-0A patent/BR112018003665A2/en not_active IP Right Cessation
- 2016-09-28 EP EP16852471.8A patent/EP3356390B1/en active Active
- 2016-09-28 IL IL314171A patent/IL314171A/en unknown
- 2016-09-28 US US15/763,706 patent/US10745447B2/en active Active
- 2016-09-28 DK DK16852471.8T patent/DK3356390T3/en active
- 2016-09-28 SG SG10202107733QA patent/SG10202107733QA/en unknown
- 2016-09-28 CN CN202210436783.2A patent/CN114606267A/en active Pending
- 2016-09-28 CN CN201680056241.5A patent/CN108137655B/en not_active Expired - Fee Related
- 2016-09-28 CA CA2996420A patent/CA2996420A1/en active Pending
- 2016-09-28 WO PCT/US2016/054143 patent/WO2017058892A2/en not_active Ceased
- 2016-09-28 AU AU2016332821A patent/AU2016332821B2/en not_active Ceased
- 2016-09-28 PL PL16852471T patent/PL3356390T3/en unknown
- 2016-09-28 PT PT168524718T patent/PT3356390T/en unknown
- 2016-09-28 IL IL257628A patent/IL257628B2/en unknown
- 2016-09-28 EP EP20212583.7A patent/EP3831842A1/en not_active Withdrawn
- 2016-09-28 JP JP2018515949A patent/JP7064214B2/en not_active Expired - Fee Related
-
2020
- 2020-07-06 US US16/921,239 patent/US11208438B2/en active Active
-
2021
- 2021-11-15 US US17/526,510 patent/US11840555B2/en active Active
-
2022
- 2022-01-28 JP JP2022011956A patent/JP7390693B2/en active Active
- 2022-05-11 AU AU2022203144A patent/AU2022203144A1/en not_active Abandoned
-
2023
- 2023-10-17 US US18/488,604 patent/US20240158450A1/en not_active Abandoned
- 2023-11-13 JP JP2023193120A patent/JP2024026088A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287122A1 (en) * | 2001-01-05 | 2005-12-29 | Children's Hospital Inc. | AAV vectors and methods |
| WO2015121501A1 (en) * | 2014-02-17 | 2015-08-20 | King's College London | Adeno-associated virus vector |
Non-Patent Citations (2)
| Title |
|---|
| KEI ADACHI ET AL: "Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing", NATURE COMMUNICATIONS, vol. 5, no. 1, 17 January 2014 (2014-01-17), XP055548821, DOI: 10.1038/ncomms4075 * |
| PRASHANTH ASURI ET AL: "Directed Evolution of Adeno-associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 20, no. 2, 1 February 2012 (2012-02-01), pages 329 - 338, XP002730957, ISSN: 1525-0024, [retrieved on 20111122], DOI: 10.1038/MT.2011.255 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3356390A4 (en) | METHODS AND COMPOSITIONS FOR VIRAL VECTORS AVOIDING ANTIBODIES | |
| FR24C1050I1 (en) | CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3759218A4 (en) | METHODS AND COMPOSITIONS FOR ANTIBODY AVOIDING VIRAL VECTORS | |
| MA46525A (en) | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | |
| PT3443009T (en) | ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
| EP3405190A4 (en) | METHODS FOR INDUCING AN IMMUNE RESPONSE | |
| MA46952A (en) | RADIO-MARKED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING | |
| EP3390643A4 (en) | PLASMIDIC CONSTRUCTS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS AND METHODS OF USE | |
| EP3331571A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | |
| EP3423089A4 (en) | ANTI-TIGIT ANTIBODIES | |
| MA53355A (en) | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3334757A4 (en) | ANTI-TIGIT ANTIBODIES | |
| EP3297671A4 (en) | ANTI-ROR1 ANTIBODIES | |
| DK3316909T5 (en) | ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS | |
| EP3430170A4 (en) | METHODS FOR CHARACTERIZING GENOMES | |
| EP3302706A4 (en) | COMPOSITIONS AND METHODS FOR DEGRADATION OF HARDLY FOLDED PROTEINS | |
| EP3307321A4 (en) | MULTI-SPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS | |
| EP3310383A4 (en) | COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION | |
| EP3423091A4 (en) | COMPOSITIONS AND METHODS FOR INDUCING HIV-1 ANTIBODIES | |
| EP3328429A4 (en) | PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMS | |
| EP3492591A4 (en) | ANTI-B7-H4 ANTIBODIES | |
| EP3526247A4 (en) | ANTI-IL1-RAP ANTIBODIES | |
| MA42829A (en) | COMPOSITIONS DERIVED FROM PLACENTA AND PROCESSES FOR PRODUCING THEM | |
| EP3328362A4 (en) | MODULAR COMPOSITIONS FOR TRAPPING SOLUBLE BIOMOLECULES AND ASSOCIATED METHODS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180307 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/015 20060101AFI20190416BHEP Ipc: C12N 15/864 20060101ALI20190416BHEP Ipc: A61K 39/23 20060101ALI20190416BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190729 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/015 20060101AFI20190723BHEP Ipc: A61K 39/23 20060101ALI20190723BHEP Ipc: C12N 15/864 20060101ALI20190723BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1257410 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200320 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20200812 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1356324 Country of ref document: AT Kind code of ref document: T Effective date: 20210215 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016051841 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210407 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: HGF GMBH, CH |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3356390 Country of ref document: PT Date of ref document: 20210421 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210414 |
|
| REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20210120 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1356324 Country of ref document: AT Kind code of ref document: T Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210420 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210520 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2865487 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211015 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016051841 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| 26N | No opposition filed |
Effective date: 20211021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210520 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210928 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230527 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160928 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230816 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20230911 Year of fee payment: 8 Ref country code: IT Payment date: 20230810 Year of fee payment: 8 Ref country code: IE Payment date: 20230809 Year of fee payment: 8 Ref country code: GB Payment date: 20230810 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230810 Year of fee payment: 8 Ref country code: PT Payment date: 20230927 Year of fee payment: 8 Ref country code: PL Payment date: 20230814 Year of fee payment: 8 Ref country code: FR Payment date: 20230808 Year of fee payment: 8 Ref country code: DK Payment date: 20230914 Year of fee payment: 8 Ref country code: DE Payment date: 20230802 Year of fee payment: 8 Ref country code: BE Payment date: 20230818 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231002 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20231001 Year of fee payment: 8 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602016051841 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250328 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20240930 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20241001 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20240928 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241001 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250401 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240928 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240928 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240928 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240929 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20251104 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210120 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240929 |